Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
6.8% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
8
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
2.0% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
12
users have liked this narrative
2
users have commented on this narrative
19
users have followed this narrative
8 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.9% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
15
users have liked this narrative
4
users have commented on this narrative
16
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
LifeStance Health Group
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Digital Advances Will Strain Mental Health Care Yet Recovery Awaits
Key Takeaways Increased competition from digital and integrated health providers, alongside clinician turnover, threatens growth in patient volume, market share, and margins. Regulatory changes and costly technology investments may slow expansion and limit profitability, despite growing mental health awareness and insurance coverage.
View narrative
US$6.50
FV
17.7% undervalued
intrinsic discount
14.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Ambarella
AN
AnalystLowTarget
Consensus Narrative from 12 Analysts
Geopolitical Strain And Chip Rivalry Will Undermine Future Value
Key Takeaways Geopolitical risks and industry shifts threaten supply chain stability, cost structure, and market position, leading to heightened unpredictability in revenues and margins. Growing competition and customer self-sufficiency undermine pricing power and profitability, while reliance on core markets and R&D spending heighten financial vulnerability.
View narrative
US$50.02
FV
32.4% overvalued
intrinsic discount
12.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
PTC Therapeutics
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Rising Healthcare Cost Containment And Delayed Approvals Will Erode Margins
Key Takeaways Increasing regulatory delays, pricing constraints, and competition threaten PTC's ability to profitably launch and sustain new rare disease therapies. Reliance on a shrinking product portfolio and persistent cash burn heighten the risk of revenue decline and potential shareholder dilution.
View narrative
US$44.00
FV
12.7% overvalued
intrinsic discount
-21.56%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Peloton Interactive
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Declining Hardware Sales And Cost Pressures Will Curb Future Prospects
Key Takeaways Plateauing sales and market saturation, combined with vulnerability to supply chain costs, threaten future revenue, margins, and cash flow. Shifts toward holistic wellness and tech innovation, plus regulatory and privacy pressures, erode Peloton's competitive advantage and long-term profitability.
View narrative
US$5.00
FV
56.8% overvalued
intrinsic discount
-2.46%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
4 days ago
author updated this narrative
Rumble
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Regulatory Risks And Competition Will Limit Revenue But B2B Will Revive
Key Takeaways Heavy reliance on niche branding and creator incentives may pressure margins amid rising regulatory and content moderation risks. Growth is challenged by intense competition and advertiser hesitation, limiting mainstream appeal and potential revenue scale.
View narrative
US$9.00
FV
13.9% undervalued
intrinsic discount
20.86%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Ultragenyx Pharmaceutical
AN
AnalystLowTarget
Consensus Narrative from 20 Analysts
Rising Clinical Risks Will Depress Biotech Pipeline Yet Invite Rebound
Key Takeaways Ultragenyx's promising late-stage pipeline and orphan drug approvals face significant risks from clinical setbacks, pricing pressures, and high R&D costs, impacting future profitability. Heavy reliance on a limited product portfolio, potential biosimilar competition, and challenges in global commercialization threaten long-term revenue growth and margin expansion.
View narrative
US$38.23
FV
23.8% undervalued
intrinsic discount
14.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Sweetgreen
AN
AnalystLowTarget
Consensus Narrative from 12 Analysts
Rising Costs And Oversaturation Will Constrain Margins And Spur Efficiency
Key Takeaways Rising input and labor costs, along with execution missteps, threaten profit recovery and may hinder growth despite automation and digital initiatives. Fast expansion risks oversaturating markets, while competitive pressures and volatile costs could limit margin improvement and long-term earnings potential.
View narrative
US$10.00
FV
5.6% undervalued
intrinsic discount
13.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
PROCEPT BioRobotics
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress
Key Takeaways Growth potential driven by demographic trends and innovation faces threats from competition, pricing pressure, and possible market shifts to non-device treatments. Expansion and recurring revenue are promising, but high costs, reimbursement risks, and geopolitical factors could constrain margins and profitability.
View narrative
US$51.00
FV
22.1% undervalued
intrinsic discount
26.48%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
C3.ai
AN
AnalystLowTarget
Consensus Narrative from 13 Analysts
Open-source AI Will Erode Revenue And Margins
Key Takeaways Proliferation of open-source AI and vertical integration by large clients threaten C3.ai's market relevance and revenue growth prospects. Increasing compliance costs, talent shortages, and persistent losses challenge C3.ai's profitability and long-term competitiveness.
View narrative
US$13.00
FV
33.7% overvalued
intrinsic discount
11.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies